NDAORALCAPSULE
Approved
Jun 2018
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
NUPLAZID (pimavanserin tartrate) by Acadia Pharmaceuticals is unclear. First approved in 2018.
Drug data last refreshed 19h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NUPLAZID (pimavanserin tartrate) is an oral small-molecule antipsychotic approved in 2018 that works through inverse agonist and antagonist activity at serotonin 5-HT2A and 5-HT2C receptors. The exact mechanism remains incompletely characterized but is believed to involve modulation of serotonergic pathways distinct from dopamine blockade.
Peak12.4 years to LOE
NUPLAZID is at peak market stage with 44 linked job openings, indicating active commercial expansion and team growth at Acadia Pharmaceuticals.
Mechanism of Action
unclear. However, the effect of pimavanserin could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT 2A receptors and to a lesser extent at serotonin 5-HT 2C receptors.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Acadia Pharmaceuticals is hiring 2 roles related to this product
Worked on NUPLAZID at Acadia Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.